NCT04238039

Brief Summary

Results of the study and of 5 years follow up of depressed patients who participated in the study during 2014-2015. We will locate the participants and will interview them will use the same questionnaires to evaluate their depressive symptoms. We will also measure the time to relapse.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
16

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Dec 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 14, 2019

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 18, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 23, 2020

Completed
9 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2020

Completed
Last Updated

January 23, 2020

Status Verified

January 1, 2020

Enrollment Period

2 months

First QC Date

January 18, 2020

Last Update Submit

January 18, 2020

Conditions

Followin Ketamine Treatment

Keywords

Major Depressive Disorder, ketamine, follow up, relapse

Outcome Measures

Primary Outcomes (1)

  • Time to relapse

    Medications

    5 years

Eligibility Criteria

AgeUp to 90 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants in the ketamine study

You may qualify if:

  • Participants in the ketamine study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Revital Amiaz

Ramat Gan, RI, 52621, Israel

RECRUITING

MeSH Terms

Conditions

Depressive Disorder, MajorRecurrence

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental DisordersDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Psychiatry Department B

Study Record Dates

First Submitted

January 18, 2020

First Posted

January 23, 2020

Study Start

December 14, 2019

Primary Completion

February 1, 2020

Study Completion

April 1, 2020

Last Updated

January 23, 2020

Record last verified: 2020-01

Locations

IL(1)